TABLE 1

Patient characteristics at screening (intention-to-treat population)

FF/UMEC/VINon-ELLIPTA MITTTotal
Patients154515473092
Age years67.8±8.7867.8±8.5967.8±8.68
Male837 (54)818 (53)1655 (54)
BMI kg·m−227.84±5.93
n=1536
28.05±6.05
n=1538
27.95±5.99
n=3074
COPD exacerbation history in the prior 12 months
 Moderate
  0409 (26)405 (26)814 (26)
  1639 (41)645 (42)1284 (42)
  ≥2497 (32)497 (32)994 (32)
 Severe
  01349 (87)1361 (88)2710 (88)
  1155 (10)139 (9)294 (10)
  ≥241 (3)47 (3)88 (3)
 Moderate/severe
  0363 (23)361 (23)724 (23)
  1615 (40)610 (39)1225 (40)
  ≥2567 (37)576 (37)1143 (37)
CAT score20.8±6.76
n=1543
20.5±6.62
n=1547
20.7±6.69
n=3090
Peripheral blood eosinophil count#n=605n=572n=1177
 <150 cells·µL−1208 (34)223 (39)431 (37)
 ≥150 cells·µL−1397 (66)349 (61)746 (63)
Actual prior medication use strata
 ICS+LAMA+LABA1226 (79)1235 (80)2461 (80)
 ICS+LABA126 (8)126 (8)252 (8)
 LABA+LAMA192 (12)183 (12)375 (12)
 Missing1 (<1)3 (<1)4 (<1)

Data are presented as n, mean±sd or n (%). FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol; MITT: multiple-inhaler triple therapy; BMI: body mass index; CAT: COPD Assessment Test; ICS: inhaled corticosteroid; LAMA: long-acting muscarinic receptor antagonist; LABA: long-acting β2-agonist. #: historical eosinophils were recorded as the most recent measure taken within the previous 36 months; : stratum is considered missing if the combination of maintenance treatments taken in the 14 days prior to randomisation do not meet any of the three defined strata groups.